RAD50 and neoplasm: With respect to MB, not only has it been sporadically described in NBS patients [25, 26], but heterozygous germline or somatic NBN, RAD50 and MRE11 mutations were discovered in MB patients, implying their potential role as haploinsufficient tumour suppressors for MB development [27, 28, 29, 30].